Zydus Lifesciences Ltd on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit.
"We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing.
The inspection was conducted from April 21-25, 2025.
"The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said.
The company is confident of addressing the observations expeditiously, it added.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
